The Cell Therapy That Couldn't Convince 9 Out of 12 Experts
An FDA advisory panel voted 9–3 against Capricor's deramiocel for Duchenne heart disease, citing "fragile" data and suspicious statistical changes. With the PDUFA decision three weeks away, the odds of approval just got a lot worse.
An FDA advisory panel just looked at Capricor Therapeutics' cell therapy for Duchenne muscular dystrophy heart disease and said, essentially, "we're not buying it." The vote wasn't even close.
On July 29, the Cellular, Tissue, and Gene Therapies Advisory Committee (CTGTAC) voted 9–3 that deramiocel does not have substantial evidence of effectiveness for treating cardiomyopathy in Duchenne muscular dystrophy (DMD). Zero abstentions. That's 75% of the panel saying no, which is the regulatory equivalent of your friends voting on where to eat dinner and only one table wanting sushi.
The vote is technically non-binding. The FDA doesn't have to listen. But historically, when an advisory committee rejects a cell or gene therapy this decisively, the agency tends to agree. The formal decision is due August 22, 2026, and the odds of approval just got a lot worse.
A Fight Over the Rulebook
The real drama here isn't just about whether deramiocel works. It's about whether Capricor played by the rules when analyzing its own data.
Deramiocel is made from donated heart-derived cells (called cardiosphere-derived cells) that are infused into patients. The idea is elegant: deliver healthy cardiac cells to slow the heart deterioration that eventually kills most DMD patients. Capricor tested it in two studies, HOPE-2 (Phase 2) and HOPE-3 (Phase 3), measuring upper-limb function and cardiac health.
Capricor says HOPE-3 worked. The company reported that deramiocel slowed upper-limb decline by 54% versus placebo and slowed cardiac function decline by 91%, both statistically significant. On paper, those are impressive numbers.
The FDA looked at the same data and reached a very different conclusion. The problem? Capricor changed its statistical analysis plan (SAP), the pre-set playbook for how to crunch the numbers, after the study was already done. The company says the changes were finalized before anyone peeked at the results. FDA reviewers disagree, arguing the original plan didn't show a significant difference between deramiocel and placebo.
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
Think of it like a basketball game where one team tries to change the scoring rules at halftime. Even if the new rules make sense, the other side is going to be suspicious.
The FDA Wasn't Subtle About Its Concerns
FDA briefing documents released before the meeting were blunt. Reviewers called the cardiac data "difficult to interpret" and couldn't find a single subgroup of patients that clearly benefited from treatment. They also flagged something sneaky about the trial's design: patients getting deramiocel had more allergic reactions than those on placebo, which may have tipped off participants (and their doctors) about who was getting the real thing.
That matters because the main measure, a test of upper-limb function called PUL 2.0, involves some subjective judgment. If patients or clinicians suspected they were on the active drug, it could unconsciously bias the results. FDA reviewers specifically warned that this "functional unblinding" weakens confidence in the numbers.
Perhaps most damning: the FDA noted that patients' heart function was normal on average when they entered the trial. If their hearts weren't clearly failing yet, it's hard to prove you're treating cardiomyopathy.
This Isn't Capricor's First Rejection
The company has been here before. In July 2025, the FDA issued a Complete Response Letter (CRL) for deramiocel, basically a formal rejection, saying Phase 2 data alone didn't cut it. Capricor came back with Phase 3 HOPE-3 results in hand, and the FDA agreed to take another look.
Now that second look has produced a second round of skepticism. Analysts who had been bullish on the stock are facing a reckoning. Before the AdCom vote, firms like B. Riley ($63 target), Piper Sandler ($58), and Cantor Fitzgerald ($62) had all raised price targets, with Cantor arguing the market was only pricing in about a 25% chance of approval. That confidence looks misplaced in hindsight.
Why This Matters Beyond One Company
Duchenne muscular dystrophy affects roughly 1 in 3,500 to 5,000 boys born worldwide. It's a brutal genetic disease that destroys muscle over time, and cardiomyopathy (progressive heart failure) is now the leading cause of death. Current treatment is borrowed from the general heart-failure playbook: ACE inhibitors, beta-blockers, and similar drugs started early and aggressively. None of them fix the underlying problem.
Existing DMD gene therapies, like exon-skipping drugs, barely touch cardiac muscle. There is no approved treatment specifically designed for Duchenne heart disease. The unmet need is enormous, and deramiocel was supposed to fill that gap.
That context makes the panel's vote especially painful for patients and families. Several spoke at the meeting, urging the committee to consider how few options they have. The panel clearly wrestled with that tension but ultimately concluded the science wasn't there yet.
Can the FDA Overrule Its Own Panel?
Technically, yes. Advisory committee votes are recommendations, not orders. The FDA approved Aduhelm (aducanumab) for Alzheimer's in 2021 despite a nearly unanimous negative vote, a decision that sparked massive controversy and multiple resignations from the committee.
But that precedent is the exception, not the rule. A study of FDA decisions from 2010 to 2021 found that approvals against negative votes happened roughly once per year across all drug types. In the cell and gene therapy space specifically, recent history has been even less forgiving. Multiple rare-disease therapies have been rejected or delayed over the past year as the agency tightens its evidentiary standards.
For deramiocel, the math is ugly: a prior CRL, a 9–3 negative vote, FDA reviewers who questioned the data, and disputed statistical methods. That's a lot of headwinds for one PDUFA date.
What Happens Next
The clock is ticking toward August 22. Capricor will make its case that the totality of evidence, HOPE-2, HOPE-3, five years of open-label follow-up data, supports approval. The FDA will weigh that against its own concerns about post-hoc analysis, potential unblinding, and whether the trial even enrolled the right patients.
If history is any guide, the most likely outcome is another rejection. But "most likely" isn't "certain," and in a disease where every new option matters, even a long shot is worth watching.
Clinical & Regulatory5 min read
The Eye Drug That Took Three Rejections to Finally Win Over the FDA
After three FDA rejections and a dramatic appeal that went over the review division's head, Outlook Therapeutics' Lytenava just became the first FDA-approved ophthalmic bevacizumab for wet AMD. Now comes the harder part: selling it in an $8.5 billion market where doctors have used the off-label version for decades.
